Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078805 · ClinicalTrials.gov registry record
Study of FORTEO Use in Subjects in the Community Setting
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 4,167
- Enrollment target
NCT01078805: Completed study, sponsored by Eli Lilly and Company.
NCT01078805 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 4,167 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01078805 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 4,167 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials
Primary Outcome
Non-vertebral fragility fracture is defined as low trauma fracture, such as a fall from standing height. It is binary outcome (Yes/No). Percentage of participants = number of participants with new Non-Vertebral Fragility Fracture/ number of participants at risk \* 100.
Interventions
- DRUG FORTEO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,167 participants |
| Start Date | 2003-08 |
| Est. Completion | 2011-02 |
What the finished NCT01078805 record still lists
NCT01078805 is an observational study that tracks outcomes without assigning an intervention. Its 4,167 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which FORTEO is the first listed.
NCT01078805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01078805 about?
NCT01078805 is a clinical study titled "Study of FORTEO Use in Subjects in the Community Setting". The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials
What is the current status of trial NCT01078805?
This trial is currently completed. The enrollment target is 4,167 participants. The study started on 2003-08. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01078805?
The interventions under investigation include: FORTEO (DRUG).
Who is sponsoring clinical trial NCT01078805?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06593353 · 4,165 participants · NA
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia